Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines

Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines

Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Companies in the pharmaceutical industry must shift from L1 (lowest-bid) costing to Life Cycle Cost Analysis (LCCA) to achieve long-term cost optimization, improve decision-making, and enhance sustainability

Indian companies must make their own intermediates and support small industries: Dr. K. Nagaiah, Chief Scientist, CSIR - IICT, Hyderabad

Indian companies must make their own intermediates and support small industries: Dr. K. Nagaiah, Chief Scientist, CSIR - IICT, Hyderabad

Indian companies must make their own intermediates and support small industries: Dr. K. Nagaiah, Chief Scientist, CSIR - IICT, Hyderabad

Developing basic technology for personalized medicine: Dr. Paidi Yella Reddy, Founder & CEO, Sapala Organics

Developing basic technology for personalized medicine: Dr. Paidi Yella Reddy, Founder & CEO, Sapala Organics

Developing basic technology for personalized medicine: Dr. Paidi Yella Reddy, Sapala Organics

Advances in genetic testing, fertility preservation, and ART are reshaping reproductive care across India: Dr. Umesh N Jindal, Director, Jindal IVF

Advances in genetic testing, fertility preservation, and ART are reshaping reproductive care across India: Dr. Umesh N Jindal, Director, Jindal IVF

Dr. Jindal reflects on bridging accessibility gaps between urban and rural regions, the ethical and emotional aspects of family building, and how initiatives like adoption facilitation centers align with his lifelong mission to help couples realize the dream of parenthood

Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India

Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India

Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth

Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries

Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries

We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.

We have consistently expanded our business in India: Vinod Paremal, President & MD, Evonik, India Region

We have consistently expanded our business in India: Vinod Paremal, President & MD, Evonik, India Region

Evonik's six innovation growth fields are: Sustainable nutrition, healthcare solutions, advanced food ingredients, membranes, cosmetic solutions, and additive manufacturing

My aim is to help the pharmaceutical industry develop a winning strategy: Dr Rupali Paranjape

My aim is to help the pharmaceutical industry develop a winning strategy: Dr Rupali Paranjape

Dr Rupali Paranjape, an experienced regulatory and compliance consultant and author of Blue Ocean of Compliance shares insights on her book in an interview with Thomas C Thottathil, Editor, www.indianpharmapost.com

The focus in FY 23 for most players would be international markets and ROW exports: Ankit Poddar, director, Candle Partners

The focus in FY 23 for most players would be international markets and ROW exports: Ankit Poddar, director, Candle Partners

Candle Partners, an investment banking & advisory service for M&A among others, has closed many deals in the healthcare space. Ankit Poddar, Director, Candle Partners spoke to Thomas C Thottathil, Editor, Indianpharmapost.com about the prospects for the industry.

We continue to invest in R&D and new product development: Anish Bafna, CEO & MD, Healthium Medtech

We continue to invest in R&D and new product development: Anish Bafna, CEO & MD, Healthium Medtech

Healthium Medtech, a company focused on products used in surgical, post-surgical and chronic care has ramped up its play in the global healthcare industry. In an interview with Thomas C. Thottathil, Editor, Indian Pharma Post, Anish Bafna, CEO and MD, Healthium Medtech outlines his plans

We have built new AI platforms like REILI to meet current needs: Chander Shekhar Sibal, Sr. Vice-President, Fujifilm India

We have built new AI platforms like REILI to meet current needs: Chander Shekhar Sibal, Sr. Vice-President, Fujifilm India

Fujifilm has been at the forefront of medical imaging and healthcare informatics. It’s developing new AI platforms to address medical challenges. Chander Shekhar Sibal, Sr. Vice-President, Fujifilm India gives us an insight in an interview with Thomas C. Thottathil, Editor, indianpharmapost.com

Venus Remedies aims to achieve Rs 1000 crore turnover by 2025: Saransh Chaudhary, President, Global Critical Care Division, Venus Remedies and CEO, Venus Medicine Research Centre

Venus Remedies aims to achieve Rs 1000 crore turnover by 2025: Saransh Chaudhary, President, Global Critical Care Division, Venus Remedies and CEO, Venus Medicine Research Centre

Saransh Chaudhary, President, Global Critical Care Division, Venus Remedies and CEO, Venus Medicine Research Centre In conversation with Thomas C Thottathil, Editor, www.indianpharmapost.com identified key areas that the company is focusing on in its Mission 2025

Indian pharma companies must become the global benchmark of quality: Amit Jaju, Sr. MD, India, Ankura Consulting

Indian pharma companies must become the global benchmark of quality: Amit Jaju, Sr. MD, India, Ankura Consulting

Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements

Glaucoma is the leading cause of irreversible blindness in India: Mr. Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals

Glaucoma is the leading cause of irreversible blindness in India: Mr. Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals

As the world celebrates World Glaucoma Week (March 7-13th), Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals, an authority on eye diseases spoke to Thomas C Thottathil, Editor, indianpharmapost.com, on the seriousness of Glaucoma

We plan to expand into the US market this year: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

We plan to expand into the US market this year: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward

BDR plans to enter the regulated markets this year: Raheel Shah, Director, BDR Group of Companies

BDR plans to enter the regulated markets this year: Raheel Shah, Director, BDR Group of Companies

BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post

We expect to turn profitable in two years: M Satyendra (Satish), Managing Director, Athena Global Technologies & MedleyMed

We expect to turn profitable in two years: M Satyendra (Satish), Managing Director, Athena Global Technologies & MedleyMed

MedleyMed is present across the pharma and healthcare value chain. It offers digital solutions to all stake holders and is in the process of expanding its operations in India and USA. In an interview with Thomas C Thottathil, M Satyendra (Satish), Managing Director, Athena Global Technologies & MedleyMed discussed his plans and opportunities in India

Ascent Meditech chalks out ambitious growth plans: Rajiv Mistry, Founder & Managing Director, Ascent Group

Ascent Meditech chalks out ambitious growth plans: Rajiv Mistry, Founder & Managing Director, Ascent Group

Ascent Meditech has set benchmarks in introducing pain management products in India. The company has embarked on a new marketing campaign as it plans to enter new markets. Rajiv Mistry, Founder & Managing Director, Ascent Group shares his perspective with Thomas C Thottathil on the road ahead for the company and industry

More women than men open up on mental health issues: Krishna Veer Singh, Co-Founder & CEO, Lissun

More women than men open up on mental health issues: Krishna Veer Singh, Co-Founder & CEO, Lissun

Mental health issues are a cause for concern and in a conservative society like India. Thomas C Thottathil spoke to Krishna Veer Singh, Co-Founder and CEO of Lissun, a young start-up working in the space of mental health

We plan to move to other geographies as we expand: Jeya Kumar, Founder and MD, RaphaCure

We plan to move to other geographies as we expand: Jeya Kumar, Founder and MD, RaphaCure

The tele-heath market in India is expected to touch US $ 5.4 billion by 2025 and the adoption of tele-health has accelerated with the onset of Covid-19 in 2020. We caught up with Jeya Kumar, Founder and MD, RaphaCure, a prominent player in this segment and he outlined the opportunities that lie ahead for this segment

Startup

Digitization